U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula 2C6H11O7.Cu
Molecular Weight 453.8408
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of COPPER GLUCONATE

SMILES

C([C@]([H])([C@]([H])([C@@]([H])([C@]([H])(C(=O)[O-])O)O)O)O)O.C([C@]([H])([C@]([H])([C@@]([H])([C@]([H])(C(=O)[O-])O)O)O)O)O.[Cu+2]

InChI

InChIKey=OCUCCJIRFHNWBP-IYEMJOQQSA-L
InChI=1S/2C6H12O7.Cu/c2*7-1-2(8)3(9)4(10)5(11)6(12)13;/h2*2-5,7-11H,1H2,(H,12,13);/q;;+2/p-2/t2*2-,3-,4+,5-;/m11./s1

HIDE SMILES / InChI

Molecular Formula C6H11O7
Molecular Weight 195.1476
Charge -1
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula Cu
Molecular Weight 63.5456
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6526221http://fs1.agrian.com/pdfs/CORE_7.5_Copper_EDTA_Label.pdfhttps://www3.epa.gov/pesticides/chem_search/ppls/019713-00509-20110705.pdfhttp://www.drugfuture.com/chemdata/tetraamminecopper-sulfate.html | https://cameochemicals.noaa.gov/chemical/3026https://www.ncbi.nlm.nih.gov/pubmed/24106015 | https://www.ncbi.nlm.nih.gov/pubmed/20942456http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits_-_Report/2009/11/WC500013010.pdfhttps://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a84d61a4-8e7f-4be1-aba6-f633b334aafc | http://www.sciencedirect.com/science/article/pii/S0167488912000158https://www.ncbi.nlm.nih.gov/pubmed/15704330 | https://www.ncbi.nlm.nih.gov/pubmed/12425037 | https://www.ncbi.nlm.nih.gov/pubmed/1599240 | http://www.certisusa.com/pdf-labels/Kocide3000_label.pdf | http://www.pesticideinfo.org/Detail_Chemical.jsp?Rec_Id=PC33524http://www.emdmillipore.com/US/en/product/Copper-di-ammonium-Titriplex-solution,MDA_CHEM-105217http://www.drugfuture.com/chemdata/schweizer-s-reagent.html | http://pubs.acs.org/doi/abs/10.1021/ed062p878?journalCode=jceda8 | http://pubs.acs.org/doi/abs/10.1021/ed019p356https://www.ncbi.nlm.nih.gov/pubmed/16971307DOI: 10.1107/s0567740869001725 Retrived from http://scripts.iucr.org/cgi-bin/paper?S0567740869001725https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=522.518 | http://www.worldofchemicals.com/chemicals/chemical-properties/cupric-glycinate.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/8556785 | https://www.ncbi.nlm.nih.gov/pubmed/2135524
Curator's Comment:: description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/24110550

Cupric fluoride (Copper fluoride) is an inorganic compound with the chemical formula CuF2. Copper fluoride is usually used as treating agent in the bonding of the resin to dentin. Cupric fluoride has being shown to be able to prevent the development of root surface caries.

CNS Activity

Curator's Comment:: Cupric ion was shown to cross the blood brain barrier in rats.

Originator

Sources: http://pubs.acs.org/doi/abs/10.1021/ja01512a012Schweizer, J. Prakt. Chem. 72, 109, 344 (1857).
Curator's Comment:: http://www.drugfuture.com/chemdata/schweizer-s-reagent.html

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
3.42 µM [Ki]
Target ID: P00450
Gene ID: 1356.0
Gene Symbol: CP
Target Organism: Homo sapiens (Human)
Target ID: Glutathione S-transferase, rat, liver
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Unknown

Approved Use

Unknown
Preventing
Unknown

Approved Use

Unknown
Preventing
Cupric glycinate

Approved Use

Indications for use. For beef calves and beef cattle for the prevention of copper deficiency, or when labeled for veterinary prescription use, for the prevention and/or treatment of copper deficiency alone or in association with molybdenum toxicity.
Primary
COPPER•MAX

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Preventing
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Diagnostic
Unknown

Approved Use

Unknown
Preventing
COPPER

Approved Use

Copper 0.4 mg/mL (Cupric Chloride Injection, USP) is indicated for use as a supplement to intravenous solutions given for total parenteral nutrition (TPN). Administration helps to maintain copper serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms.
Preventing
COPINOX

Approved Use

Copinox 4g is indicated for the prevention and treatment of copper deficiency in cattle and sheep.
PubMed

PubMed

TitleDatePubMed
Determination of protein by the biuret reaction using cupric hydroxide suspension reagent.
1960
Efficacy of burning, tillage, and biocides in controlling bacteria released at field sites and effects on indigenous bacteria and fungi.
1992 Apr
The effect of various fluoride compounds on the development of experimental root surface caries in hamsters.
1995 Dec
The effectiveness of ecologically acceptable ways of protection of field-grown tomato (Lycopersicon lycopersicum (L.) Karsten) from tomato late blight (Phytophthora infestans (Mont.) de Bary) in extreme weather conditions.
2001
X-ray absorption spectroscopy study of a copper-containing material after thermal treatment.
2006 Apr 17
Enhanced copper release from pipes by alternating stagnation and flow events.
2007 Nov 1
Synthesis and structural investigation of mono- and polynuclear copper complexes of 4-ethyl-1-(pyridin-2-yl) thiosemicarbazide.
2008 Nov 1
Generation of oxidant response to copper and iron nanoparticles and salts: Stimulation by ascorbate.
2009 Oct 30
Insight in the transport behavior of copper glycinate complexes through the porcine gastrointestinal membrane using an Ussing chamber assisted by mass spectrometry analysis.
2010 Apr
Regulation of plasminogen activator inhibitor-1 expression in endothelial cells with exposure to metal nanoparticles.
2010 May 19
Copper sulfide nanoparticles for photothermal ablation of tumor cells.
2010 Oct
Zinc prevents the copper-induced damage of cultured astrocytes.
2010 Oct
Molecular responses of human lung epithelial cells to the toxicity of copper oxide nanoparticles inferred from whole genome expression analysis.
2011 Dec 27
Rapid free chlorine decay in the presence of Cu(OH)2: chemistry and practical implications.
2011 Oct 15
Zeta potential and solubility to toxic ions as mechanisms of lung inflammation caused by metal/metal oxide nanoparticles.
2012 Apr
CuBr2--a new multiferroic material with high critical temperature.
2012 May 8
Evaluation of topically applied copper(II) oxide nanoparticle cytotoxicity in human skin organ culture.
2013 Feb
Molecular responses of mouse macrophages to copper and copper oxide nanoparticles inferred from proteomic analyses.
2013 Nov
Cytotoxicity in the age of nano: the role of fourth period transition metal oxide nanoparticle physicochemical properties.
2013 Nov 25
The modality of cell-particle interactions drives the toxicity of nanosized CuO and TiO₂ in human alveolar epithelial cells.
2013 Oct 24
Activation of Erk and p53 regulates copper oxide nanoparticle-induced cytotoxicity in keratinocytes and fibroblasts.
2014
Interference of CuO nanoparticles with metal homeostasis in hepatocytes under sub-toxic conditions.
2014
Effects of different sources of copper on Ctr1, ATP7A, ATP7B, MT and DMT1 protein and gene expression in Caco-2 cells.
2014 Jul
Dissecting copper homeostasis in diabetes mellitus.
2017 Apr
Supplementation with copper edetate in control of Haemonchus contortus of sheep, and its effect on cholinesterase's and superoxide dismutase activities.
2017 Feb
Folic acid-modified and functionalized CuS nanocrystal-based nanoparticles for combined tumor chemo- and photothermal therapy.
2017 Jun
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: Veterinary drug
44 ug twice a day
Route of Administration: Intravenous
In Vitro Use Guide
Incubation of 300-500 ul of plasma with 10 uM /L of cupric acetate resulted in the formation of products from fatty acids (malonaldehyde, measured by thiobarbituric acid assay) and cholesterol (predominantly cholest-3,5-dien-7-one, measured by gas-liquid chromatography). In the presence of Cu2+, formation of malonaldehyde and cholest-3,5-dien-7-one increased at least 10-fold over basal values.
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:27:39 UTC 2021
Edited
by admin
on Fri Jun 25 21:27:39 UTC 2021
Record UNII
RV823G6G67
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
COPPER GLUCONATE
FCC   HSDB   INCI   MART.   USP   VANDF   WHO-DD  
INCI  
Official Name English
CUPRUM GLUCONICUM
Common Name English
CUPRIC GLUCONATE [VANDF]
Common Name English
GLUCONIC ACID, COPPER(2+) SALT (2:1), D-
Common Name English
COPPER GLUCONATE [VANDF]
Common Name English
COPPER GLUCONATE [MART.]
Common Name English
COPPER GLUCONATE [WHO-DD]
Common Name English
CUPRIC GLUCONATE [MI]
Common Name English
COPPER (AS GLUCONATE)
Common Name English
GLUCONIC ACID, COPPER(2+) SALT
Common Name English
COPPER(II) GLUCONATE
Common Name English
COPPER(II)GLUCONATE
Common Name English
COPPER GLUCONATE [FCC]
Common Name English
COPPER GLUCONATE [USP]
Common Name English
COPPER GLUCONATE [INCI]
Common Name English
COPPER, BIS (D-GLUCONATO-O(SUP 1),O(SUP 2))-
Common Name English
COPPER D-GLUCONATE (1:2)
Common Name English
CUPRIC GLUCONATE
MI   VANDF  
Common Name English
COPPER(2+) D-GLUCONATE, (1:2)
Common Name English
COPPER GLUCONATE [HSDB]
Common Name English
Classification Tree Code System Code
CFR 21 CFR 184.1260
Created by admin on Fri Jun 25 21:27:40 UTC 2021 , Edited by admin on Fri Jun 25 21:27:40 UTC 2021
FDA ORPHAN DRUG 522516
Created by admin on Fri Jun 25 21:27:40 UTC 2021 , Edited by admin on Fri Jun 25 21:27:40 UTC 2021
Code System Code Type Description
EVMPD
SUB13457MIG
Created by admin on Fri Jun 25 21:27:40 UTC 2021 , Edited by admin on Fri Jun 25 21:27:40 UTC 2021
PRIMARY
FDA UNII
RV823G6G67
Created by admin on Fri Jun 25 21:27:40 UTC 2021 , Edited by admin on Fri Jun 25 21:27:40 UTC 2021
PRIMARY
MERCK INDEX
M3900
Created by admin on Fri Jun 25 21:27:40 UTC 2021 , Edited by admin on Fri Jun 25 21:27:40 UTC 2021
PRIMARY Merck Index
EPA CompTox
527-09-3
Created by admin on Fri Jun 25 21:27:40 UTC 2021 , Edited by admin on Fri Jun 25 21:27:40 UTC 2021
PRIMARY
RXCUI
2839
Created by admin on Fri Jun 25 21:27:40 UTC 2021 , Edited by admin on Fri Jun 25 21:27:40 UTC 2021
PRIMARY RxNorm
NCI_THESAURUS
C1505
Created by admin on Fri Jun 25 21:27:40 UTC 2021 , Edited by admin on Fri Jun 25 21:27:40 UTC 2021
CONCEPT Dietary Supplement
HSDB
261
Created by admin on Fri Jun 25 21:27:40 UTC 2021 , Edited by admin on Fri Jun 25 21:27:40 UTC 2021
PRIMARY
DRUG BANK
DB11246
Created by admin on Fri Jun 25 21:27:40 UTC 2021 , Edited by admin on Fri Jun 25 21:27:40 UTC 2021
PRIMARY
PUBCHEM
10692
Created by admin on Fri Jun 25 21:27:40 UTC 2021 , Edited by admin on Fri Jun 25 21:27:40 UTC 2021
PRIMARY
CAS
527-09-3
Created by admin on Fri Jun 25 21:27:40 UTC 2021 , Edited by admin on Fri Jun 25 21:27:40 UTC 2021
PRIMARY
ECHA (EC/EINECS)
208-408-2
Created by admin on Fri Jun 25 21:27:40 UTC 2021 , Edited by admin on Fri Jun 25 21:27:40 UTC 2021
PRIMARY
NCI_THESAURUS
C80050
Created by admin on Fri Jun 25 21:27:40 UTC 2021 , Edited by admin on Fri Jun 25 21:27:40 UTC 2021
PRIMARY
WIKIPEDIA
COPPER GLUCONATE
Created by admin on Fri Jun 25 21:27:40 UTC 2021 , Edited by admin on Fri Jun 25 21:27:40 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY